Mirum Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 (MXN64,457 Mil) to Dec. 2025 (MXN65,188 Mil) and
increased
from Dec. 2025 (MXN65,188 Mil) to Mar. 2026 (MXN76,530 Mil).
Mirum Pharmaceuticals's annual market cap
increased
from Dec. 2023 (MXN25,023 Mil) to Dec. 2024 (MXN43,619 Mil) and
increased
from Dec. 2024 (MXN43,619 Mil) to Dec. 2025 (MXN65,188 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mirum Pharmaceuticals's Enterprise Value for Today is MXN129,381 Mil.
Mirum Pharmaceuticals (MEX:MIRM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MIRM vs RYTM, SYRE, PTGX: Market Cap Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mirum Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (MEX:MIRM) has a Market Cap of MXN130,476 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #59 out of 1422 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Mirum Pharmaceuticals' Market Cap too high?
Mirum Pharmaceuticals' current Market Cap is MXN130,476 Mil. Based on the distribution chart, Mirum Pharmaceuticals ranks #59 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Market Cap compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #59 out of 1422 companies for Market Cap. This places Mirum Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 120.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mirum Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mirum Pharmaceuticals's current Market Cap is MXN130,476 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Market Cap of MXN130,476 Mil. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current Market Cap is MXN130,476 Mil. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Market Cap is MXN130,476 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.
Key valuation signals for MEX:MIRM:
Market Cap: MXN130,476 Mil
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
